Bempedoic acid Study 1 show positive LDL-cholesterol lowering

14 March 2019

Daiichi Sankyo’s (TYO: 4568) European subsidiary and Esperion Therapeutics (Nasdaq: ESPR) announced that positive results from the 2,230 patient, 52-week, Phase III long-term safety study of bempedoic acid were published in NEJM. The paper can be found online here.

Bempedoic acid is being developed as a convenient, once-daily, oral therapy for the treatment of patients with elevated LDL-C. Bempedoic acid and the bempedoic acid/ezetimibe combination are currently undergoing regulatory review for marketing authorization by the European Medicines Agency. A decision is expected during the first half of 2020.

Esperion granted Daiichi Sankyo exclusive rights to commercialize bempedoic acid and the bempedoic acid/ezetimibe combination pill in the European Economic Area and Switzerland in January this year, in a deal worth a potential $900 million in milestone payments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK